ARTICLE | Product Development
Lilly’s Junshi-partnered program becomes China’s first COVID-19 mAb in clinic
EMA decision on remdesivir due in weeks; U.K. groups aim for vaccine capacity, affordability
June 9, 2020 1:17 AM UTC
As EMA nears a decision on Gilead’s remdesivir to treat COVID-19 and a pair of groups take steps towards making vaccines available in the U.K., a second mAb against SARS-CoV-2 has entered clinical testing.
Eli Lilly and Co. (NYSE:LLY) and partner Shanghai Junshi Biosciences Co. Ltd. (HKEX:1877) have announced the start of a Chinese Phase I study of anti-spike mAb JS016 in healthy volunteers. Lilly will begin a complementary Phase I trial in the U.S. in the coming days. ...